Dioscin promotes osteoblastic proliferation and differentiation via Lrp5 and ER pathway in mouse and human osteoblast-like cell linesReportar como inadecuado




Dioscin promotes osteoblastic proliferation and differentiation via Lrp5 and ER pathway in mouse and human osteoblast-like cell lines - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Biomedical Science

, 21:30

First Online: 17 April 2014Received: 26 November 2013Accepted: 31 March 2014DOI: 10.1186-1423-0127-21-30

Cite this article as: Zhang, C., Peng, J., Wu, S. et al. J Biomed Sci 2014 21: 30. doi:10.1186-1423-0127-21-30

Abstract

BackgroundDioscin, a typical steroid saponin, is isolated from Dioscorea nipponica Makino and Dioscorea zingiberensis Wright. It has estrogenic activity and many studies have also reported that dioscorea plants have an effect in preventing and treating osteoporosis. However, the molecular mechanisms underlying their effect on osteoporosis treatment are poorly understood. Therefore, the present study aims to investigate the mechanism s by which dioscin promotes osteoblastic proliferation and differentiation in mouse pre-osteoblast like MC3T3-E1 cells and human osteoblast-like MG-63 cells.

ResultsWe found that dioscin 0.25 μg-ml, 0.5 μg-ml, and 1.0 μg-ml promoted MC3T3-E1 cells and MG-63 cells proliferation and differentiation dose dependently. Western blot analysis results showed that estrogen receptor α ER-α, estrogen receptor β ER-β, β-catenin and Bcl-2 protein expression increased after MC3T3-E1 cells were treated with dioscin. Quantitative reverse transcription-polymerase chain reaction RT-PCR analysis indicated that dioscin could increase the ratio of osteoprotegerin OPG-receptor activator of NF-κB ligand RANKL and up-regulate the level of Lrp5 and β-catenin. And by RNA interference analysis, we proved that the effect of dioscin increasing the ratio of OPG-RANKL was dependent on Lrp5 pathway. In addition, we also found that these effects of dioscin were abolished by ICI 182, 780 100 nM, an antagonist of ER, indicating that an ER signaling pathway was also involved. We also found that dioscin 0.25 μg-ml, 0.5 μg-ml, and 1.0 μg-ml induced MG-63 cells proliferation and differentiation in a dose-dependent manner. Western blot analysis results indicated that ER-α, ER-β and β-catenin protein expression increased after MG-63 cells were treated with dioscin.

ConclusionsThe current study is the first to reveal that dioscin can promote osteoblasts proliferation and differentiation via Lrp5 and ER pathway.

KeywordsDioscin Proliferation Differentiation Lrp5 ER Osteoporosis AbbreviationsDioDioscin

ER-αEstrogen receptor α

ER-βEstrogen receptor β

Lrp5Low-density lipoprotein receptor-related protein 5

ALPAlkaline phosphatase

OPGOsteoprotegerin

RANKLReceptor activator of NF-κB ligand

RT-PCRReverse transcription- polymerase chain reaction

OPPGOsteoporosis-pseudoglioma

HBMHigh bone mass

HRTHormone replacement therapy.

Electronic supplementary materialThe online version of this article doi:10.1186-1423-0127-21-30 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Chunfang Zhang - Jinyong Peng - Shan Wu - Yue Jin - Fan Xia - Changyuan Wang - Kexin Liu - Huijun Sun - Mozhen Liu

Fuente: https://link.springer.com/







Documentos relacionados